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Constitutively activated signal transducers and activators of transcription (STAT) factors, in particular STAT1, STAT3 and STAT5,
have been demonstrated in a variety of human tumours and cancer cell lines. However, data on the expression of these STATs in
nasopharyngeal carcinoma (NPC) are limited. In this study, the expression patterns of STAT1, STAT3 and STAT5 were
immunohistochemically examined on the archival specimens from 61 patients with NPC. Staining results of each STATs were then
correlated with the clinical parameters and prognosis of these patients. The results showed that constitutive activation of STAT3 and
STAT5 was detected in the majority, 70.5 and 62.3%, respectively, of the 61 tumour specimens. Furthermore, coexpression of
activated STAT3 and STAT5 was found in 54.1% of the specimens. In contrast, constitutive activated STAT1 could only be detected
in 8 (13.1%) cases. Surprisingly, following radiotherapy, patients with constitutive STAT5 activation, or activation of both STAT3 and
STAT5, had better disease-free survival and overall survival than those without activated STAT5. To our knowledge, this is the first
report providing the overall expression patterns and prognostic significance of specific STATs in NPC.
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Signal transducers and activators of transcription (STAT) proteins
comprise a family of transcription factors and function as
downstream effectors of many cytokine and growth factor
receptors (Darnell, 1997). Signalling pathways mediated by STATs
are critical for many normal cellular functions, including
embryonic development, organogenesis, immunological interac-
tion, growth, differentiation and survival (Buettner et al, 2002).
During cytokine or growth factor stimulation, STATs are tyrosine
phosphorylated, dimerise, and translocate into the nucleus to
regulate target gene expression (Darnell, 1997). The activation
duration of STATs under physiological conditions is usually
temporary and is tightly regulated by a number of cellular
mechanisms, such as tyrosine dephosphorylation, ubiquitin/
proteosome-mediated degradation, negative feedback loop
mediated by CIS/SOCS/JAB/SSI family of proteins, or inhibition
of STAT DNA-binding activity through association with protein
inhibitor of activated STAT (PIAS) proteins (Lin and Leonard,
2000). However, constitutively activated STATs, especially STAT1,
STAT3 and STAT5, have been found in a variety of human
tumours and cancer cell lines, including blood malignancies and
solid tumours (Turkson and Jove, 2000). In various tumour cell
lines, persistent signalling of specific STATs, in particular STAT3
and STAT5, has been shown to stimulate cell proliferation and
prevent apoptosis through upregulating a number of target genes,
such as c-Myc, cyclins and bcl-x. In contrast, inhibition of
constitutively activated STAT3 or STAT5 leads to growth
suppression or apoptosis (Buettner et al, 2002).
Nasopharyngeal carcinoma (NPC) is endemic in South-east Asia
and closely associated with Epstein–Barr virus (EBV) (Tsai et al,
1996). Epstein–Bars virus resides in NPC cells in a status called
type II latency, with only a few latent genes expressed (Brooks et al,
1992). One of these latent genes, latent membrane protein 1 (LMP-
1), has been shown to have transforming potential (Baichwal and
Sugden, 1988; Kaye et al, 1993) and is implicated in the
oncogenesis of various EBV-associated malignancies, including
NPC. LMP-1 can also interact with Janus Kinase 3 (JAK3) and
activate STAT proteins (Gires et al, 1999). In a recent study, the
JAK/STAT pathway was shown to play a role in maintaining in
vivo latency of EBV (Chen et al, 1999). Aberrant STAT activation
has also been proposed as a necessary and predisposing event for
EBV-driven tumorigenesis in immunocompetent individuals
(Chen et al, 2001).
Although the presence of constitutive STAT1, STAT3 and STAT5
activation has been demonstrated in NPC tissue (Chen et al, 2001),
data on the levels of expression of these STATs in NPC are lacking.
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affects prognosis after treatment remains unclear. This study used
immunohistochemical methods to examine the expression pattern
of STAT1, STAT3 and STAT5 in biopsy specimens of patients with
NPC and correlated the results with clinical parameters of these
patients.
MATERIALS AND METHODS
Patients and specimens
A total of 61 NPC patients with complete follow-up records and
available archival nasopharyngeal biopsy specimens were recruited
in this study. All of the 61 patients, including 49 males and 12
females, were histologically confirmed to have WHO type II
(nonkeratinising) or WHO type III (undifferentiated) NPC
(Shanmugaratnam et al, 1979). The clinical status of these patients
was determined using the 1997 UICC/AJCC staging system (Sobin
and Wittekind, 1997) after reviewing their clinical records and
image studies which included chest X-ray, abdominal sonography,
bone scan and CT scan. All patients were previously untreated and
received radiation treatment with curative intention between 1990
and 2000 at the Department of Radiation Oncology of National
Cheng Kung University Hospital. In all, 56 patients received
radiotherapy as their sole treatment modality. The other five
patients received concurrent chemotherapy with bolus infusion of
cisplatin 100mgm
 2day
 1 on the beginning day of weeks 1, 3 and
5 after the start of the radiotherapy regimen. All 61 patients
completed the full-course of radiation therapy within 9 weeks
without any interruption and received regular follow-up at our
hospital. Among the 61 patients, 41 remained disease-free for a
median follow-up period of 57.1 months, ranging from 26.3 to 151
months. In total, 20 patients suffered from loco-regional relapse
and/or distant metastasis after treatment, including nine patients
with local recurrence (one also with distant metastasis), eight
patients with recurrence in the neck (five also with distant
metastasis), two patients with both local and neck recurrence (one
also with distant metastasis) and one patient with distant
metastasis without loco-regional relapse. All the archival naso-
pharyngeal biopsy specimens used in this study were obtained
from the Department of Pathology of National Cheng Kung
University Hospital.
Immunohistochemical study
Serial 5-mm histological sections were cut, mounted on glass slides
coated with 3-aminopropyltriethoxysilane, and air-dried overnight
at room temperature. The sections were then deparaffinised in
xylene and rehydrated in ethanol. Haematoxylin and eosin (H&E)
staining was first performed in each specimen to confirm the
presence of tumour cells. Endogenous peroxidase activity was then
blocked with methanol containing 3% H2O2 for 15min. For all
sections used in this study, the antigen retrieval procedure was
performed by immersing the slides in citrate buffer (pH 6.0) and
then heating the slides in a microwave oven for 10min. The
sections were then incubated with primary antibodies using 1:25
dilution for STAT1, STAT3 and STAT5 (mouse anti-human IgG1,
Santa Cruz, CA, USA) at 41C overnight, followed by staining with
Universal Immuno-peroxidase polymer (UIP) solution (Simple
Stain MAX PO MULTI, Nichirei, Tokyo, Japan) for 30min. The
sections were finally reacted with AEC (3-amino-9-ethylcarbazole)
substrate solution (DAKO, Glostrup, Denmark) and then counter-
stained with haematoxylin before being mounted. Non-human
reactive mouse IgG1 (DAKO, Glostrup, Denmark) was used as an
isotype negative control.
The sections were then observed under a light microscope by a
pathologist (IT Jin) who was blinded to the clinical characteristics
of the patients. The degree of expression of each STAT was then
determined independently with the following rules. Intranuclear
staining of tumour cells was considered to indicate the presence of
constitutively activated STATs. Using high magnification power
( 400), five representative fields in each section were evaluated.
In total, 100 tumour cells were counted in each field. In sections
containing less than five tumour nests, all tumour nests were
evaluated. The percentage of immunoreactive tumour cells with
nuclear staining was then calculated. When equal or more than
20% of the counted tumour cells on one slide showed identifiable
nuclear staining, the slide was classified as ‘positive’ for significant
constitutive STATs activation. If less than 20% of tumour cells
showed a nuclear staining pattern, the slide was considered to
show no significant constitutive activation of STATs and was
classified as ‘negative’. Staining results of the specimens were then
correlated with the clinical characteristics of the patients.
Statistical analysis
w
2 test was used to calculate the significance of the relation between
expression of each STAT and clinical characteristics. The Kaplan–
Meier method was used in the survival analysis. Log-rank test was
used to calculate the significance of differences in the survival
analysis. Cox’s proportional hazards regression model was used to
study the influence of covariates on survival time. A probability
level of less than 0.05 (Po0.05) was considered to indicate a
significant difference.
RESULTS
Constitutive activation of STAT3 and STAT5 in the
majority of NPC specimens
Both STAT3 and STAT5 were significantly activated in a high
proportion of the NPC specimens included in this study.
Significant constitutive STAT3 activation was noted in 43
(70.5%) of the 61 samples studied, while significant constitutive
STAT5 activation was noted in 38 (62.3%) of the 61 specimens
(Table 1). In contrast, constitutive STAT1 activation could only be
detected in eight (13.1%) of the 61 cases. The intensity of
intranuclear staining varied among the specimens, and differences
of staining intensity were also noted among tumour nuclei within
the same histological section. However, strong intranuclear
staining, or intranuclear and cytoplasmic staining, was noted in
31 of the 43 specimens classified as ‘positive’ for significant
constitutive STAT3 activation (Figure 1A, B) and in 32 of the 38
specimens classified as ‘positive’ for significant constitutive STAT5
activation (Figure 1C). In contrast, most of the specimens showed
no intranuclear staining of STAT1 protein in tumour cells
(Figure 1D).
Frequent coactivation of both STAT3 and STAT5
Among the 43 specimens classified as ‘positive’ for significant
STAT3 activation, 33 were also classified as ‘positive’ for STAT5
activation. Among the remaining 18 specimens that were classified
as ‘negative’ for STAT3 activation, 13 were also classified as
‘negative’ for constitutive STAT5 activation (Table 2). The
proportion of specimens with same STAT3 and STAT5 classifica-
tion was 75.4% (46 out of 61), suggesting that STAT3 and STAT5
might be coactivated.
Constitutive activation of STAT5, or both STAT3 and
STAT5, correlates with better prognosis
Among the 61specimens stained for STAT5 protein, 38 specimens
were classified as ‘positive’ and 23 as ‘negative’ for significant
constitutive STAT5 activation. As shown in Table 1, no difference
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patients, including age, sex, TNM stage, WHO subtype classifica-
tion and treatment modalities. However, comparison of treatment
outcome among these two groups revealed that patients whose
biopsy specimens showed significant constitutive STAT5 activa-
tion had better prognosis after treatment (w
2 test, P¼0.026).
Patients who had no significant constitutive STAT5 activation on
histological sections were more likely to suffer from loco-regional
Table 1 Patient characteristics and the staining results of STAT3 and STAT5
Constitutive STAT3 activation Constitutive STAT5 activation
(+) ( ) P-value (+) ( ) P-value
Number of specimens 43 (70.5%) 18 (29.5%) 38 (62.3%) 23 (37.7%)
Clinical parameters
Age Mean7s.d. (years) 49.3711.9 44.6711.0 0.15 47.5711.4 48.6712.4 0.71
Sex Male 34 15 0.98 29 20 0.49
Female 9 3 9 3
T T1 13 6 0.31
a 13 6 0.55
a
T2 25 12 23 14
T 3 00 00
T 4 50 23
N N0 17 7 0.73
b 15 9 0.84
b
N1 18 9 16 11
N 2 61 61
N 3 21 12
Stage I 7 4 0.46
c 8 3 0.98
c
II 26 12 22 16
I I I 51 60
I V 51 24
WHO subtype II 14 7 0.37 11 10 0.37
III 29 11 27 13
Treatment modality R/T only 39 17 0.85 34 22 0.71
Concurrent C/T+R/T 4 1 4 1
Prognosis after treatment
Disease-free 32 9 0.12 30 11 0.026*
Recurrence of disease 11 9 8 12
aT1+T2 vs T3+T4.
bN0+N1 vs N2+N3.
cStage I+II vs Stage III+IV. *Statistically significant (Po0.05).
Figure 1 Staining of STAT1, STAT3 and STAT5 on serial pathological sections of a NPC biopsy specimen. (A) H&E stain. Large, vesicular nucleus with
prominent nucleolus (arrow) is noted in majority of the tumour cells. (B) Strong intranuclear (arrowheads) and cytoplasmic staining of STAT3. (C)
intranuclear (arrows) and faint cytoplasmic staining of STAT5. Nuclear STAT5 staining is also noted in endothelial cells of a nearby vessel (arrowheads). (D)
No nuclear staining of STAT1 in the tumour cells (arrows). Nuclear staining of STAT1 is noted in an infiltrating lymphocyte (arrowhead) (original
magnification  1000).
Constitutively activated STATs in nasopharyngeal carcinoma
J-R Hsiao et al
346
British Journal of Cancer (2003) 89(2), 344–349 & 2003 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
srelapse and/or distant metastasis. On the other hand, the STAT1
and STAT3 staining results showed no such correlation (w
2 test,
P¼0.36 and 0.12, respectively). This result still held true in the
survival analysis. Patients whose biopsy specimens showed
significant constitutively activated STAT5 also had better dis-
ease-free survival and overall survival than those patients who had
‘negative’ results on their biopsy specimens (Figure 2A, B; log-rank
test, Po0.01 and o0.05). Since activation of both STAT3 and
STAT5 was frequently noted in the same specimen, we then
explored whether this coactivation could have an impact on
treatment outcome. Interestingly, patients who had ‘positive’
staining results for both activated STAT3 and STAT5 (33 patients)
had significantly better overall survival and disease-free survival
than those are ‘negative’ for both staining (13 patients) (Figure 2C,
D;
wlog-rank test, Po0.05). However, the double-positive group
did not significantly predict better prognosis than the STAT5
positivity only group, both in overall survival and disease-free
survival. On the contrary, the double-positive group significantly
predicted better prognosis than the STAT3 positivity only group in
overall survival (Figure 2C,
zlog-rank test, Po0.05), implying that
STAT5 is more important in predicting prognosis than STAT3. In
figure 2C and D, although the STAT5 positivity only group has a
favourable survival curve than the other groups, there was no
statistical significance detected. This might be due to the small
number of patients in the STAT5 positivity only group (five
patients). To clarify whether the better prognostic prediction was
due to STAT5 positivity only or due to simultaneous activation of
STAT3 and STAT5, multivariate analysis was performed. In the
Cox’s regression model, only STAT5 was selected to be an
independent variable for both overall survival (hazard ratio 0.17,
P¼0.008) and disease-free survival (hazard ratio 0.37, P¼0.03),
suggesting that STAT5 is the major determinant of better
prognosis.
DISCUSSION
Constitutively activated STATs have been detected in a variety of
human tumours and cancer cell lines, including blood malig-
nancies and solid tumours. Most studies demonstrating constitu-
tive activation of STATs in solid human malignancies have used
either Western blot analysis and/or electrophoretic mobility shift
assay (EMSA) as the main methodology. However, considering the
‘lymphoepithelioma-like’ nature of NPC (Shanmugaratnam et al,
1979), applicability of these methods might be confounded by the
infiltrating lymphocytes in this tumour and is not suitable under
such conditions. Therefore, we decided to use immunohistochem-
ical methods to study the expression patterns of STATs in NPC.
The suitability of this strategy is further supported by the fact that,
in addition to their presence in lymphocytes (Figure 1D),
constitutively activated STATs are also noted in other nontumour
cells (Figure 1C).
A recent study found persistent STAT1, STAT3 and STAT5
activation in NPC tissue (Chen et al, 2001). However, insufficient
Table 2 Results of STAT3 and STAT5 staining on the 61 NPC
specimens
Constitutive STAT3 activation
(+) ( ) Total
Constitutive STAT5
activation
(+) 33 (54.1%) 5 (8.2%) 38
( ) 10 (16.4%) 13 (21.3%) 23
Total 43 18 61
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Figure 2 Survival of NPC patients as a function of the staining results of
STAT5, or both STAT3 and STAT5: (A) Overall survival as a function of
results of STAT5 staining, (B) disease-free survival as a function of results of
STAT5 staining, (C) overall survival as a function of results of both STAT3
and STAT5 staining, and (D) disease-free survival as a function of results of
both STAT3 and STAT5 staining.
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expression of these STATs in NPC. This study has provided the
first evidence that significant constitutively activated STAT3 and
STAT5 are present in over half of NPC patients (Table 1), while
STAT1 activation is present in only a minor proportion of these
patients. The intranuclear staining intensity of STAT3 and STAT5
was strong in many of the tissue specimens (Figure 1), suggesting
that STAT signalling is very active in this malignancy. We also
noted that constitutively activated STAT3 and STAT5 frequently
coexisted in the same specimen. It has been shown that different
STATs can be activated by the same ligand and/or intracellular
tyrosine kinase (Ruff-Jamison et al, 1994; Carlesso et al, 1996;
Olayioye et al, 1999). Simultaneously persistent STATs activation
is also noted in a variety of human cancers (Turkson and Jove,
2000). As many cellular genes regulating cell cycle and apoptosis,
such as c-Myc, cyclin D and bcl-x are downstream targets of
STAT3 and STAT5 (Buettner et al, 2002), it is reasonable to
speculate that persistent signalling of STATs, particularly STAT3
and STAT5, may play a role in tumorigenesis of NPC.
Although STAT1 activation has been reported in some tumours
and cell lines, STAT1 activation is associated with tumour
suppression rather than proliferation in most conditions (Buettner
et al, 2002). In a recent study, activated STAT1 was also shown to
negatively regulate angiogenesis, tumorigenicity and metastasis of
tumour cells (Huang et al, 2002). STAT1 deficiency has also been
found in a variety of tumour cell lines and this deficiency is
responsible for the lack of INF-g-mediated tumour suppression
effects (Wong et al, 1997; Abril et al, 1998; Sun et al, 1998; Pansky
et al, 2000). Therefore, it was not unexpected that constitutively
activated STAT1 was found in only eight (13.1%) of the 61 NPC
specimens. In our study, only one of the 20 patients suffering from
disease recurrence had significant STAT1 activation.
The presence of constitutively activated STAT5 and coactivation
of STAT3 and STAT5 was correlated with better prognosis in this
study. Using Cox’s regression model, STAT5 was identified to be
an independent prognosis-predicting factor. Although STAT3 was
found in 70.5% of these NPC patients, it is not an independent
prognostic factor for survival. The lack of statistical significance
for STAT3 might result from the frequent co-activation of STAT3
and STAT5, or the relative small number of patients in this series.
It is also possible that STAT5 is truly the only determinant of
better prognosis. The prognostic significance of each STATs in
NPC deserves further investigation.
In most conditions, activation of STAT3 or STAT5 up-regulates
cell cycle progression and antiapoptotic genes in cells. Therefore,
recognizing the constitutive activation of STAT5 as a good
prognostic factor is out of our expectation. However, in a number
of different studies, activated STATs have been reported to play a
role in differentiation and apoptosis (Bromberg and Darnell, 2000).
Activated STAT3 has been proposed to facilitate mammary gland
involution by inducing extensive epithelial apoptosis through
upregulating IGFBP-5 (Chapman et al, 1999). Transfection of a
constitutively activated STAT5 mutant into an IL-3-dependent Ba/
F3 cell line induces expression of bcl-xL and pim-1 and renders the
cell line factor-independent. However, IL-3 treatment of the factor-
independent cell line resulted in apoptosis within 24h, or
differentiation followed by cell death. This apoptosis might have
been due to the concomitant upregulation of JAB/SOCS-1/SSI-1
and p21 by the super-active STAT5 signaling (Nosaka et al, 1999).
Thus, differences in the fate of cells might be determined by the
activation intensity and duration of specific STATs and may be
cell-type specific. It has been shown that cellular STATs can also be
activated through interactions between JAK3 and LMP-1 protein of
EBV (Gires et al, 1999). LMP-1 can also upregulate expression of
epidermal growth factor receptor (EGFR) (Miller et al, 1995),
which may then modulate expression of specific STATs upon
ligand stimulation (Petersen and Haldosen, 1998; Kloth et al, 2002;
Leong et al, 2002). Interestingly, in line with our findings, despite
the fact that LMP-1 of EBV is known for its transforming ability
and promotes cellular proliferation in various studies (Baichwal
and Sugden, 1988; Kaye et al, 1993), tumours with LMP-1
expression tend to have better prognosis in EBV-associated
malignancies such as Hodgkin’s disease (Montalban et al, 2000;
Glavina-Durdov et al, 2001) and NPC (Hu et al, 1995). Regarding
the intimate association between STATs and NPC, further
clarification of the relation between STAT signalling and the gene
expression pattern of EBV may shed light on the pathogenesis of
this unique malignancy and might have future therapeutic
applications.
In conclusion, by using immunohistochemical methods, we
demonstrated that constitutive activation of STAT3 and STAT5
was present in the majority of biopsy specimens from patients with
NPC. Besides, constitutive coactivation of STAT3 and STAT5 was
frequently noted in the same specimen. By Cox’s regression
analysis, activation of STAT5 is an independent factor that predicts
better prognosis in NPC patients after radiotherapy.
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